S. Grimm

发表

Glioblastoma: a method for predicting response to antiangiogenic chemotherapy by using MR perfusion imaging--pilot study.

J. Raizer, T. Carroll, R. Levy, 2010, Radiology.

Anaplastic Astrocytoma

S. Grimm, M. C. Chamberlain, 2020, Definitions.

A phase II trial evaluating the effects and intra-tumoral penetration of bortezomib in patients with recurrent malignant gliomas

A. Rademaker, J. Rosenow, M. Bredel, 2016, Journal of Neuro-Oncology.

Metastatic glioblastoma: case presentations and a review of the literature

A. Rademaker, J. Raizer, I. Helenowski, 2012, Journal of Neuro-Oncology.

State of the art and perspectives in the treatment of glioblastoma REVIEW

S. Grimm, M. Chamberlain, 2009 .

Using methylation profiling to diagnose systemic metastases of pleomorphic xanthoastrocytoma

M. Snuderl, J. Wolinsky, C. Horbinski, 2019, Neuro-oncology advances.

Economics of Malignant Gliomas: A Critical Review.

J. Raizer, C. Bennett, J. Mckoy, 2015, Journal of oncology practice.

Brainstem Glioma: A Review

M. Chamberlain, S. Grimm, 2013, Current Neurology and Neuroscience Reports.

Financial burden experienced by patients undergoing treatment for malignant gliomas.

A. Rademaker, J. Raizer, C. Bennett, 2014, Neuro-oncology practice.

Hodgkin's Lymphoma: A Review of Neurologic Complications

M. Chamberlain, S. Grimm, 2010, Advances in hematology.

Rituximab, methotrexate, procarbazine, and vincristine followed by consolidation reduced-dose whole-brain radiotherapy and cytarabine in newly diagnosed primary CNS lymphoma: final results and long-term outcome.

D. Correa, L. Deangelis, P. Morris, 2013, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Pemetrexed in the treatment of relapsed/refractory primary central nervous system lymphoma

A. Rademaker, J. Raizer, A. Evens, 2012, Cancer.

Intratumoral hemorrhage after thrombolysis in a patient with glioblastoma multiforme

L. Deangelis, S. Grimm, 2007, Neurology.

A multi-institutional phase II trial of bevacizumab for recurrent and refractory meningioma

P. Wen, D. Schiff, J. Raizer, 2022, Neuro-oncology advances.

Pharmacokinetics and efficacy of pemetrexed in patients with brain or leptomeningeal metastases

A. Rademaker, W. Gradishar, J. Raizer, 2013, Journal of Neuro-Oncology.

Phase I study of arsenic trioxide and temozolomide in combination with radiation therapy in patients with malignant gliomas

J. Raizer, R. Levy, K. Muro, 2012, Journal of Neuro-Oncology.

A phase II trial of PTK-787 (PTK/ZK) in recurrent or progressive meningiomas

J. Raizer, K. Muro, S. Grimm, 2008 .

Diffusion abnormalities of the corpus callosum in patients receiving bevacizumab for malignant brain tumors: suspected treatment toxicity

J. Raizer, A. Ragin, A. Nemeth, 2014, Journal of Neuro-Oncology.

A phase I trial of LBH589 and bevacizumab for recurrent high-grade glioma (HGG).

R. Beroukhim, P. Wen, D. Schiff, 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Treatment of Brain Metastases: Chemotherapy

S. Grimm, 2012, Current Oncology Reports.

Long-term glioblastoma survival following recovery from cytomegalovirus colitis: A case report

M. Tate, C. Horbinski, S. Grimm, 2019, Journal of Clinical Neuroscience.

Primary CNS lymphoma with intraocular involvement

J. Blay, E. Thiel, D. Schiff, 2008, Neurology.

Primary intraocular lymphoma: an International Primary Central Nervous System Lymphoma Collaborative Group Report.

J. Blay, E. Thiel, J. Pulido, 2007, Annals of oncology : official journal of the European Society for Medical Oncology.

Adult primary spinal cord tumors

S. Grimm, M. Chamberlain, 2009, Expert review of neurotherapeutics.

Interim analysis of a phase I/II study of panobinostat in combination with bevacizumab for recurrent glioblastoma.

Katrina H. Smith, R. Beroukhim, P. Wen, 2013 .

Anaplastic Astrocytoma

S. Grimm, Thomas J. Pfiffner, 2020, Current Treatment Options in Neurology.

State of the art and perspectives in the treatment of glioblastoma.

M. Chamberlain, S. Grimm, 2012, CNS oncology.

A phase 2 trial of single‐agent bevacizumab given in an every‐3‐week schedule for patients with recurrent high‐grade gliomas

M. Bredel, J. Raizer, M. Nicholas, 2010, Cancer.

Extensive brainstem infiltration, not mass effect, is a common feature of end-stage cerebral glioblastomas.

R. Stupp, J. Raizer, C. Horbinski, 2019, Neuro-oncology.

A phase II study of bevacizumab and erlotinib after radiation and temozolomide in MGMT unmethylated GBM patients

K. Aldape, W. Yung, A. Rademaker, 2015, Journal of Neuro-Oncology.

A multi-center prospective study of re-irradiation with bevacizumab and temozolomide in patients with bevacizumab refractory recurrent high-grade gliomas

M. Mehta, J. Raizer, M. Nicholas, 2021, Journal of Neuro-Oncology.

Bevacizumab and other novel therapies for recurrent oligodendroglial tumors.

M. Chamberlain, S. Grimm, 2015, CNS oncology.

A phase II trial of arsenic trioxide and temozolomide in combination with radiation therapy for patients with malignant gliomas

M. Mehta, J. Raizer, I. Helenowski, 2012, Journal of Neuro-Oncology.

Phase I study of panobinostat in combination with bevacizumab for recurrent high-grade glioma

R. Beroukhim, P. Wen, D. Schiff, 2012, Journal of Neuro-Oncology.

Phase II study of panobinostat in combination with bevacizumab for recurrent glioblastoma and anaplastic glioma.

Katrina H. Smith, R. Beroukhim, P. Wen, 2015, Neuro-oncology.

Lymphomatosis cerebri presenting with orthostatic hypotension, anorexia, and paraparesis

E. Bigio, S. Grimm, A. Keswani, 2012, Journal of Neuro-Oncology.

A randomized phase I/II study of ABT-888 in combination with temozolomide in recurrent temozolomide resistant glioblastoma: an NRG oncology RTOG group study

M. Gilbert, M. Mehta, F. Lieberman, 2015, Journal of Neuro-Oncology.

Primary CNS lymphoma with bilateral symmetric hypothalamic lesions presenting with panhypopituitarism and diabetes insipidus

P. Kopp, M. Molitch, B. Layden, 2011, Pituitary.

Choroid Plexus Tumors

M. Chamberlain, S. Grimm, 2016 .

Prognosis of older patients with low-grade glioma: A retrospective study.

A. Rademaker, K. Swanson, C. Bridge, 2017, Integrative cancer science and therapeutics.

19. Leptomeningeal Metastases

M. Chamberlain, S. Grimm, 2012 .

Combined Modality Approaches in the Management of Adult Glioblastoma

M. Mehta, J. Raizer, S. Grimm, 2011, Front. Oncol..

A phase II trial of PTK787/ZK 222584 in recurrent or progressive radiation and surgery refractory meningiomas

A. Rademaker, J. Raizer, M. Mrugala, 2014, Journal of Neuro-Oncology.

A phase 2 trial of verubulin for recurrent glioblastoma: a prospective study by the brain tumor investigational consortium (BTIC)

S. Rosenfeld, S. Phuphanich, M. Chamberlain, 2014, Journal of Neuro-Oncology.

Anaplastic astrocytoma.

M. Chamberlain, S. Grimm, 2016, CNS oncology.

Risks of Diuretic Usage following Stroke

M. Reding, S. Grimm, M. Churchill, 2004, Neurorehabilitation and neural repair.

Neural stem cell delivery of an oncolytic adenovirus in newly diagnosed malignant glioma: a first-in-human, phase 1, dose-escalation trial.

Atique U. Ahmed, R. Stupp, M. Tate, 2021, The Lancet. Oncology.

A Phase I/II Study of Intrathecal Trastuzumab in HER-2 Positive Cancer with Leptomeningeal Metastases: Safety, Efficacy, and Cerebrospinal Fluid Pharmacokinetics.

W. Gradishar, N. Lin, J. Raizer, 2022, Neuro-oncology.

Retinopathy in survivors of primary central nervous system lymphoma

L. Deangelis, L. Abrey, S. Grimm, 2006, Neurology.

Concordance of patient and caregiver reports in evaluating quality of life in patients with malignant gliomas and an assessment of caregiver burden.

A. Rademaker, J. Raizer, I. Helenowski, 2014, Neuro-oncology practice.

Outcome of discontinuing bevacizumab prior to malignant glioma progression

J. Raizer, S. Grimm, Wendy J. Sherman, 2012, Journal of Neuro-Oncology.

A phase II trial of PTK787/ZK 222584 (PTK787) in recurrent high-grade meningioma.

A. Rademaker, J. Raizer, M. Mrugala, 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

NEURO/MEDICAL ONCOLOGY

Scott N. Hwang, Katrina H. Smith, Susan M. Chang, 2013 .

Phase II study of verubulin (MPC-6827) for the treatment of subjects with recurrent glioblastoma naïve to treatment with bevacizumab.

L. Recht, S. Rosenfeld, J. Raizer, 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Multicenter phase II study of temozolomide and myeloablative chemotherapy with autologous stem cell transplant for newly diagnosed anaplastic oligodendroglioma

C. Brennan, N. Schultz, D. Louis, 2017, Neuro-oncology.

Secondary CNS myeloma with remission after systemic CNS-penetrating agents

Luis García Fernández, S. Grimm, V. Gondi, 2022, Neuro-oncology advances.

MNGO-04PHASE II TRIAL OF BEVACIZUMAB IN PATIENTS WITH SURGERY AND RADIATION REFRACTORY PROGRESSIVE MENINGIOMA

P. Wen, D. Schiff, J. Raizer, 2015 .

19. Leptomeningeal Metastases

M. Chamberlain, S. Grimm, 2012 .

CMET-22. INTRATHECAL (IT) TRAZTUZUMAB (T) FOR THE TREATMENT OF LEPTOMENINGEAL METASTASES (LM) IN PATIENTS (PTS) WITH HUMAN EPIDERMAL GROWTH FACTOR RECEPTOR 2-POSITIVE (HER2+) CANCER: A MULTICENTER PHASE 1/2 STUDY

W. Gradishar, J. Raizer, A. Lassman, 2018, Neuro-Oncology.

A randomized phase II trial of concurrent temozolomide (TMZ) and radiotherapy (RT) followed by dose dense compared to metronomic TMZ and maintenance cis-retinoic acid for patients with newly diagnosed glioblastoma multiforme (GBM)

L. Deangelis, A. Lassman, L. Abrey, 2007 .